Arbutus Biopharma Corporation · NASDAQ:ABUS
Arbutus Biopharma — Tekmira Pharmaceuticals — Merger or Acquisition (January 2015)
16 slides from Arbutus Biopharma's merger presentation, Jan 28, 2015
Slide 1: Creating a Leading Global HBV Therapeutics Company
Creating a Leading Global HBV Therapeutics Company
Slide 2: Forward Looking Statements
Forward pocking Statements ore eran oe i Soe os occa coats nar ey aa Pee er tance ad te tore ews Hoan 9, aang ere), Foveskiy see pont 5 th Once ep: opal angie src ni popes Wh respec oe co lr ed ga, ppt eur elon oh aetna ped rat abe ed aanys poste Whle Teimea con Ieee assanploné fo be sense ong ter t
Slide 3: Chronic HBV — greatest global unmet medical need
Chronic HBV — greatest global unmet medical need (Chronic HBV infections @ HBV Genotypes (A-H)
Slide 4: Our Goal - an all oral, curative therapy for HBV
Our Goal - an all oral, curative therapy for HBV + HBV biology is complex — More complex than HCV + HBV persists by 1. Replicating continually in liver hepatocytes 2. Expressing viral antigens that suppress the immune response 3. Establishing a stable cccDNA reservoir in the nucleus * Curative thera
Slide 5: Provide a cure by delivering multiple mechanisms of action
* Provide a cure by delivering multiple mechanisms of action against the virus — Aggressively suppress viral replication — Stimulate or reactivate the immune system — Eliminate cccDNA * Provide a finite treatment regimen To succeed in achieving HBV Cure, all facets of HBV persistence need to be addr
Slide 6: Transaction Highlights
Transaction Highlights * Combined company well positioned to capitalize on the global market opportunity in HBV and create significant long-term value for shareholders + Creates the industry’s leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need + Eigh
Slide 7: Proven Leadership
Proven Leadership + Mark Murray, Chief Executive Officer (Tekmira) + Patrick Higgins, President and Chief Operating Officer (OnCore, former Pharmasset) + Bruce Cousins, Chief Financial Officer (Tekmira) + Michael Sofia, Chief Scientific Officer (OnCore, former Pharmasset) + William Symonds, Chief De
Slide 8: Building the "HBV Solutions" Company
Building the “HBV Solutions’ Company Hepatitis B is a bigger market than Hepatitis C Building a portfolio of HBV assets that will lead to curative therapy Differentiating from the potential competition in multiple ways: 1. Utilization of combination therapy with a three-pillar approach 2. Nine compo
Slide 9: Tekmira Development Pipeline
Tekmira Development Pipeline SE SET cocDNA. Preclinical ad Replication Stimulation’ —_ Inhibition’ Lead IND Source: THH-HBY e , a a a eceny e = =>» Usd tem asa k= WZ» ares) e Leneedton os =a TS — Cet e — polelarery aren cee haus t ) = =» Aequiston of Enantgen cecDNA License from poles 0 == eae verse
Slide 10: Relationship with Baruch S. Blumberg Institute
Relationship with Baruch S. Blumberg Institute Blumberg Institute Is One of the Leading Research Institutes Focused on HBV + License Agreements with Blumberg and Drexel University +» Research Funding and Collaboration Agreement with (Drexel) — February 2014 and November 2014 Blumberg — October 2014
Slide 11: TKM-HBV: Targeting Multiple HBV Transcripts
TKM-HBV: Targeting Multiple HBV Transcripts Trigger sites that target 3 viral transcripts , Trigger sites that target all 4 transcripts Tekmita | Os Design an anti-HBV RNAi Trigger ‘payload’ that is: — Potent - reduces viral protein production, especially HBsAg — Universal - effective against all ge
Slide 12: Combination Development Strategy
Combo Combination Development Strategy
Slide 13: Advancing Non-HBV Programs
Advancing Non-HBV Programs Focus _ Indication Product Research ical Phase! Phasell _Phaseilll Gastrointestinal Neuroendocrine Tumors TKM-PLK1: Gl-NET Adrenocortical Carcinoma TKM-PLK(: ACC Hepatocellular Carcinoma TKM-PLK1: HCC Ebola Virus Infection TKM-Ebola = Ebola Virus Infection TKM-Ebola- Cinco
Slide 14: OnCore-Tekmira Transaction Details
OnCore-Tekmira Transaction Details * OnCore will become a wholly-owned subsidiary of Tekmira + Merger of equals as determined by the treasury stock method + Implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 201
Slide 15: Conclusion
Conclusion * Combined company well positioned to capitalize on the global market opportunity in HBV and create significant long-term value for shareholders * Creates the industry's leading portfolio of therapeutic approaches to cure HBV, addressing a significant unmet medical need + 8 unique drug ca
Slide 16: Creating a Leading Global HBV Therapeutics Company
Creating a Leading Global HBV Therapeutics Company
Tekmira Pharmaceuticals — Merger or Acquisition (January 2015) on 6ix